- Last Updated on December 03, 2013
For more information, click here
25th Annual Birmingham Jingle Bell Run/Walk for Arthritis
Click here for more information
The Comprehensive Arthritis, Musculoskeletal and Autoimmunity Center’s mission is to generate new understanding and apply all knowledge to the diagnosis and treatment of patients with arthritis, musculoskeletal and autoimmune diseases. This charge includes integrating and promoting fundamental research with clinical care, developing and applying new diagnostics and therapeutics, educating the public about arthritis, musculoskeletal, and autoimmune diseases, and training future investigators and health care professionals. Est. 1977
- to facilitate rheumatic disease research through Research Core facilities, which provide scientifically rigorous, state-of-the-art techniques necessary for improved understanding of disease pathogenesis and the development of new treatments, including:to support outstanding Pilot & Feasibility research projects drawing on the unique strengths of the RDCC research base and using innovative tools and approaches in biomedical science; and
- Comprehensive Flow Cytometry Core (J. D. Mountz, Director; O. Kutsch, T. Randall, Co-Directors)
- Analytic Imaging and Immunoreagent Core (K. T. Keyser, Director; M. A. Accavitti-Loper, C. Weaver, Co-Directors)
- Analytical Genomics and Transgenics Core (R. A. Kesterson, Director; J. Edberg, D. Absher, Co-Directors)
- to support outstanding Pilot & Feasibility research projects drawing on the unique strengths of the RDCC research base and using innovative tools and approaches in biomedical science; and
- to provide career development and career enrichment activities to enhance both the mentorship of talented investigators as independent researchers and the continuing education of all of our investigators.
- Facilitating Treat-to-Target Using Novel Health Technology with Decision Support (Curtis);
- Adaptive Immune Responses to Gut Microbiota in Juvenile & Adult Spondyloarthritis (Elson);
- The Effects of Urate Lowering Therapy on Inflammation, Endothelial function, and Blood Pressure (Saag, KG; Calhoun, D, MPI)
- Determinants of Achieving Target Serum Urate in Gout and Safety of Gout Treatments (Singh, J, PI)
- A Novel Centralized 'Virtual' Gout Clinic for Chronic Gout Management (Curtis, J.R., PI)
UAB Deep South Arthritis and Musculoskeletal Center for Education and Research on Therapeutics (Kenneth G. Saag, MD, MSc, Director; AHRQ 1U19 HS021110)
- Improve safety and effectiveness of MSD therapeutics through 4 projects that build on our past work and address the programmatic areas of comparative effectiveness research (CER), tool development, health systems interventions and translating research into practice:Educate health care practitioners, patients, caregivers, pavers, and policy makers; and
- Comparative Effectiveness of NSAIDs vs. Narcotics after Joint Replacement Surgery (w/ FORCE registry & UMass);
- A Novel Tool and Multi-Modal Intervention for Improving Osteoporosis Treatment Adherence (w/ Kaiser)
- Informed Consent Tools for Pragmatic Clinical Trials in Musculoskeletal Diseases (w/ CMTP & JHU)
- Assessing Comparative Effectiveness of Biologics and Communicating Risk in Juvenile and Adult Inflammatory Arthritis (w/ CARRA and Yale)
- Educate health care practitioners, patients, caregivers, pavers, and policy makers; and
- Develop concept briefs and other nascent research and education ideas into full scale projects and products for dissemination in cooperation with AHRQ, the CERTS Scientific Forum, and our large network of partners.
- Genetically-Defined Microbe Core;
- Molecular Pathology and Human Cell/Tissue Core; and
- Gnotobiotic and Genetically-Engineered Mouse Core.
The UAB Division of Gastroenterology and Hepatology is ranked nationally and internationally as a leading center for digestive and liver disorders. UAB continues to lead the advancement of Gastroenterology and Hepatology, having participated in over 60 clinical trials in the past 5 years. These trials offer the latest in drug therapy and other novel approaches to digestive disorders including inflammatory bowel disease (Crohn’s disease, ulcerative colitis) and viral hepatitis.
The UAB Osteoporosis Prevention and Treatment Clinic provides complete, expert care, from clinical and therapeutic services to helpful education and information programs. Specialists in the fields of osteoporosis, nutrition, and physical therapy work collectively to help patients treat existing conditions and prevent further complications with proper medication, diet, and exercise.
UAB is participating in ResearchMatch.org, the first national online, volunteer-recruitment registry developed to improve the way biomedical research is conducted across the country. This easy-to-use tool can help match researchers and people who want or need to volunteer for clinical trials. Volunteers are notified electronically that they are a possible match, and then they may decide whether or not to release their contact information to member researchers. Register online at ResearchMatch.org.
To learn more, click here.
Treatment Efficacy and Toxicity in Rheumatoid Arthritis Database and Repository (S. Louis Bridges, Jr., MD, PhD, NIAMS RC2 AR058964)
While treatment of rheumatoid arthritis (RA) has improved dramatically in the last 10 years, there is a large variability in effectiveness, toxicity and price of therapeutic options. Dr. Bridges and colleagues have developed the TETRAD initiative as a means to create a cohort with prospectively collected treatment response data coupled with biological samples to enable research to allow improvements in the efficacy and cost-effective use of existing agents in patients with RA. This project has created collaborative network of leading academic investigators which has been collecting treatment response data and biologic samples in RA patients starting MTX or biologic agents. This proof-of-concept has seeded the creation of a large, sustainable database and repository to better understand the molecular basis of treatment and rapidly accelerate translational research in RA.
Genomics of Lupus (Robert P. Kimberly, MD (site PI); NIAID P01 AI083194)
The ability to scan the entire genome provides an unprecedented opportunity for novel discovery of critical pathways in disease pathogenesis. The SLE Genetics Consortium, a productive multi-institutional consortium of lupus investigators, matches the capacity for current state-of-the-art genome-wide technology with large phenotypically characterized participant collections which provide appropriate statistical power for genome-wide studies. Building on previous success in European-Americans, this project pursues a trans-racial mapping approach which provides a unique opportunity to identify both variants in common and variants which may be population specific. Project 1 explores the HLA region variation in >6000 subjects who are African-American, Amerindian admixed Hispanics, or Asians and grounded at HLA-DRB2 using existing genome data for European-derived subjects. Projects 2-4 explore the whole genome by evaluating 1.8 million markers in 6000 non-European subjects with replication, fine mapping, and trans-racial mapping in 9000 additional subjects. The resulting level of understanding promises to establish the genetic etiology of lupus, spawn new diagnostics, prognostics, and therapeutics which provide therapeutic benefit to this and many related illnesses.
To learn more, click here.
Genes and Phenotypes (GAP) studies of Immunologic and Inflammatory Pathways (Robert P. Kimberly, MD (site PI); NIAMS RC2 AR059092)
Center for Clinical and Translational Science (Robert P. Kimberly, MD, Director, NCATS 5UL1 RR025777)
The UAB CCTS will enhance human health by driving scientific discovery and dialogue across the bench, bedside, and community continuum. The CCTS Components support this overall mission in a highly integrative network of relationships. Success in creating such an environment is dependent upon success in achieving five strategic priorities: 1) enhancing research infrastructure; 2) promoting investigator education, training and development; 3) accelerating discovery across the T1 interface; 4) expanding value-added partnerships; and 5) building sustainability.
To learn more, click here.
This multidisciplinary program consists of over 100 UAB Faculty who identify themselves as basic or clinical immunologists representing multiple Departments and Schools at UAB. With over $45M in FY 2008 from the National Institute of Allergy and Infectious Diseases (NIAID) and the National Institute of Arthritis, Musculoskeletal, and Skin Diseases (NIAMS), the two NIH funding agencies most focused on host defense, immunology, and inflammation research, this represented about 25% of the entire NIH research portfolio at UAB.
To learn more, click here.